SCHEMBL6159701

SCHEMBL6159701

Cc1ccc(N)cc1C(=O)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
TDP1 Q9NUW8 3/20 0.53
L3MBTL1 Q9Y468 3/20 0.50
TSHR P16473 2/20 0.50
KMT2A Q03164 2/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPK1 P28482 1/20 0.50
LMNA P02545 1/20 0.46
RAB9A P51151 4/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 3/20 0.44
NPC1 O15118 1/20 0.44
BLK P51451 1/20 0.44
BTK Q06187 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12369122 0.88 ALDH1A1 (0.54) ALDH1A1TDP1L3MBTL1TSHRKMT2A
SCHEMBL23812434 0.86 ALDH1A1 (0.63) ALDH1A1TDP1L3MBTL1TSHRKMT2A
SCHEMBL18717240 0.85 TDP1 (0.59) ALDH1A1TDP1L3MBTL1TSHRKMT2A
SCHEMBL20695025 0.85 ALDH1A1 (0.57) ALDH1A1TDP1L3MBTL1TSHRKMT2A
SCHEMBL20052028 0.84 ALDH1A1 (0.53) ALDH1A1TDP1L3MBTL1TSHRKMT2A
SCHEMBL6160019 0.83 KMT2A (0.52) ALDH1A1TDP1L3MBTL1TSHRKMT2A
SCHEMBL8130349 0.82 ALDH1A1 (0.54) ALDH1A1TDP1L3MBTL1TSHRKMT2A
SCHEMBL31448226 0.82 ALDH1A1 (0.54) ALDH1A1TDP1L3MBTL1TSHRKMT2A
SCHEMBL24152237 0.82 ALDH1A1 (0.54) ALDH1A1TDP1L3MBTL1TSHRKMT2A
SCHEMBL7258885 0.82 ALDH1A1 (0.54) ALDH1A1TDP1L3MBTL1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1178969-B1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS BLACK JAMES FOUNDATION (GB) 2005-07-13 EP disclosed
US-20030195240-A1 Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands JAMES BLACK FOUNDATION LIMITED (GB) 2003-10-16 US disclosed
US-6479531-B1 Gastrin and cholecystokinin receptor ligands JAMES BLACK FOUNDATION LIMITED (GB) 2002-11-12 US disclosed
EP-1178969-A1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 2002-02-13 EP disclosed
CN-1325385-A Gastrin and cholecystokinin receptor ligands BLACK JAMES FOUNDATION (GB) 2001-12-05 CN disclosed
WO-2001085167-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PROTON PUMP INHIBITORS AND GASTRIN/CHOLECYSTOKININ RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 2001-11-15 WO disclosed
WO-2000027823-A1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 2000-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195240-A1 Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands GIPR, CCKAR, CCKBR ALDH1A1 4620/4885TDP1 4747/4885L3MBTL1 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.